-
公开(公告)号：US20090137784A1
公开(公告)日：2009-05-28
申请号：US12353225
申请日：2009-01-13
IPC分类号： C07K16/18
CPC分类号： C07K16/2863 , A61K38/00 , C07K14/71 , C07K2317/21 , C07K2317/34 , C07K2317/622 , G01N2333/71
摘要： Antibodies and polypeptides that bind to and/or modulate the activity of receptors in the epidermal growth factor family are provided herein.
摘要翻译： 本文提供结合和/或调节表皮生长因子家族中受体活性的抗体和多肽。
-
公开(公告)号：US07951360B2
公开(公告)日：2011-05-31
申请号：US12535083
申请日：2009-08-04
CPC分类号： C07K14/55 , A61K38/00 , G01N33/6869 , G01N2333/55 , G01N2500/04
摘要： The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2Rα). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2α using yeast surface display to generate mutants with increased affinity for IL-2Rα.
摘要翻译： 本发明涉及对IL-2α-受体亚单位（IL-2Rα）具有增加的亲和力的IL-2突变体。 因此，本发明包括具有改善的生物效能的IL-2突变体。 本发明还包括使用酵母表面显示产生IL-2α的定向进化以产生具有增加的对IL-2Rα的亲和力的突变体的方法。
-
公开(公告)号：US07569215B2
公开(公告)日：2009-08-04
申请号：US10894833
申请日：2004-07-19
CPC分类号： C07K14/55 , A61K38/00 , G01N33/6869 , G01N2333/55 , G01N2500/04
摘要： The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2Rα). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2α using yeast surface display to generate mutants with increased affinity for IL-2Rα.
摘要翻译： 本发明涉及对IL-2α受体亚单位（IL-2Rα）具有增加的亲和力的IL-2突变体。 因此，本发明包括具有改善的生物效能的IL-2突变体。 本发明还包括用于使用酵母表面显示产生IL-2α的定向进化以产生具有增加的对IL-2Rα的亲和力的突变体的方法。
-
公开(公告)号：US20100036097A1
公开(公告)日：2010-02-11
申请号：US12535083
申请日：2009-08-04
IPC分类号： C07K14/55
CPC分类号： C07K14/55 , A61K38/00 , G01N33/6869 , G01N2333/55 , G01N2500/04
摘要： The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2Rα). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2α using yeast surface display to generate mutants with increased affinity for IL-2Rα.
摘要翻译： 本发明涉及对IL-2α受体亚单位（IL-2Rα）具有增加的亲和力的IL-2突变体。 因此，本发明包括具有改善的生物效能的IL-2突变体。 本发明还包括用于使用酵母表面显示产生IL-2α的定向进化以产生具有增加的对IL-2Rα的亲和力的突变体的方法。
-
公开(公告)号：US09683231B2
公开(公告)日：2017-06-20
申请号：US13993930
申请日：2011-12-16
CPC分类号： C12N15/1079 , C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , C12Q2600/178 , G01N33/5023
摘要： The invention is directed to a method of characterizing a mechanism of action of an agent (e.g., a chemotherapeutic agent, a genotoxic agent). The method comprises contacting a plurality of populations of cells with an agent to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein said gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the agent is determined, thereby obtaining an shRNA signature of the agent, so as to identify one or more genes that mediate a response to the agent, thereby characterizing the mechanism of action of the agent. The invention is also directed an article of manufacture for characterizing a mechanism of action of a chemotherapeutic or genotoxic agent.
-
公开(公告)号：US07371370B2
公开(公告)日：2008-05-13
申请号：US10910087
申请日：2004-08-03
IPC分类号： A61K38/19
CPC分类号： C12N5/0634 , A61K38/00 , C07K14/535 , C12N2501/22 , C12N2503/02
摘要： The present invention relates to granulocyte colony stimulating factor (“G-CSF”) polypeptide analog compositions. The concept detailed herein provides methods for screening G-CSF analogs, designed with one or more substitutions to amino acids, and selecting analogs for use as G-CSF replacements or antagonists, and may be generalizable beyond G-CSF analogs as well. In addition, pharmaceutical compositions and methods of use are provided for analogs so selected.
摘要翻译： 本发明涉及粒细胞集落刺激因子（“G-CSF”）多肽类似物组合物。 本文详细描述的概念提供了用于筛选具有氨基酸的一个或多个取代的G-CSF类似物的筛选方法，以及选择用作G-CSF替代物或拮抗剂的类似物，并且可以推广到除了G-CSF类似物之外。 此外，为所选择的类似物提供药物组合物和使用方法。
-
公开(公告)号：US20140134635A1
公开(公告)日：2014-05-15
申请号：US13993930
申请日：2011-12-16
IPC分类号： G01N33/50
CPC分类号： C12N15/1079 , C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , C12Q2600/178 , G01N33/5023
摘要： The invention is directed to a method of characterizing a mechanism of action of an agent (e.g., a chemotherapeutic agent, a genotoxic agent). The method comprises contacting a plurality of populations of cells with an agent to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein said gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the agent is determined, thereby obtaining an shRNA signature of the agent, so as to identify one or more genes that mediate a response to the agent, thereby characterizing the mechanism of action of the agent. The invention is also directed an article of manufacture for characterizing a mechanism of action of a chemotherapeutic or genotoxic agent.
摘要翻译： 本发明涉及一种表征药剂（例如，化学治疗剂，遗传毒性剂）的作用机制的方法。 该方法包括使多个细胞群与待评估的试剂接触，其中每个细胞群具有一个由小发夹RNA（shRNA）靶向的感兴趣基因，其中所述感兴趣的基因调节细胞死亡和多个基因 调节细胞死亡的目标在多个细胞群体中。 确定每种细胞群体对试剂的反应性，从而获得试剂的shRNA标签，以鉴定介导对试剂的反应的一种或多种基因，从而表征试剂的作用机制。 本发明还涉及用于表征化学治疗剂或遗传毒性剂的作用机制的制品。
-
公开(公告)号：US20140206544A1
公开(公告)日：2014-07-24
申请号：US13994057
申请日：2011-12-16
CPC分类号： C12N15/1079 , C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , C12Q2600/178 , G01N33/5023
摘要： In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents. In another aspect, the invention is directed to a method of determining whether a patient population treated with a first agent would benefit from a treatment using the first agent in combination with one or more additional agents. In yet another aspect, the invention is directed to method of determining whether a formulation of one or more agents maintains a mechanism of action of the one or more agents when unformulated.
摘要翻译： 一方面，本发明涉及一种表征药剂组合的作用机理的方法。 所述方法包括使多个细胞群与待评估的试剂的组合接触，其中每个细胞群具有一个由小发夹RNA（shRNA）靶向的感兴趣基因，并且其中感兴趣的基因调节细胞死亡和多个 的调节细胞死亡的基因被靶向于多个细胞群体。 确定每种细胞群与药剂组合的反应性，从而获得试剂组合的shRNA标签，以鉴定介导对试剂组合的反应的一种或多种基因，从而表征 代理商的组合。 在另一方面，本发明涉及一种确定用第一药剂治疗的患者群体是否将受益于使用第一药剂与一种或多种另外的药剂联合治疗的方法。 在另一方面，本发明涉及确定一种或多种试剂的制剂是否在未配制时维持所述一种或多种试剂的作用机制的方法。
-
公开(公告)号：US08349311B2
公开(公告)日：2013-01-08
申请号：US13088045
申请日：2011-04-15
CPC分类号： C07K14/55 , A61K38/00 , G01N33/6869 , G01N2333/55 , G01N2500/04
摘要： The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2Rα). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2α using yeast surface display to generate mutants with increased affinity for IL-2Rα.
摘要翻译： 本发明涉及对IL-2α-受体亚单位（IL-2Rα）具有增加的亲和力的IL-2突变体。 因此，本发明包括具有改善的生物效能的IL-2突变体。 本发明还包括使用酵母表面显示产生IL-2α的定向进化以产生具有增加的对IL-2Rα的亲和力的突变体的方法。
-
公开(公告)号：US09670486B2
公开(公告)日：2017-06-06
申请号：US13994057
申请日：2011-12-16
CPC分类号： C12N15/1079 , C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , C12Q2600/178 , G01N33/5023
摘要： In one aspect, the invention is directed to a method of characterizing a mechanism of action of a combination of agents. The method comprises contacting a plurality of populations of cells with a combination of agents to be assessed, wherein each population of cells have one gene of interest targeted by a small hairpin RNA (shRNA) and wherein the gene of interest regulates cell death and a plurality of genes that regulate cell death are targeted in the plurality of populations of cells. A responsiveness of each population of cells to the combination of agents is determined, thereby obtaining an shRNA signature of the combination of agents so as to identify one or more genes that mediate a response to the combination of agents, thereby characterizing the mechanism of action of the combination of agents. In another aspect, the invention is directed to a method of determining whether a patient population treated with a first agent would benefit from a treatment using the first agent in combination with one or more additional agents. In yet another aspect, the invention is directed to method of determining whether a formulation of one or more agents maintains a mechanism of action of the one or more agents when unformulated.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.032 秒)
